The word, used by singer Charli XCX as an album title, is defined as "characterized by a confident, independent, and ...

There was a time when “The Simpsons” was a universal pop culture touchstone. President George H.W. Bush criticized it from ...

Texas, USA-based biopharma Lexicon Pharmaceuticals (Nasdaq: LXRX) was trading nearly 36% lower on Friday morning.

The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic ...

Although not bound to the committee’s recommendations, the FDA does take them into consideration when making decisions on approval. A regulatory decision is expected on December 20, 2024. If approved, ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel ...

Lexicon Pharmaceuticals shares tumbled in premarket trading Friday after a Food and Drug Administration advisory committee's negative vote on the biopharmaceutical company's Zynquista as an adjunct to ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

Lexicon还与Viatris签订了独家许可协议，授权后者在美国和欧洲以外地区商业化sotagliflozin，Viatris支付了$25 million的预付款，并有可能获得额外的里程碑付款。分析师公司Piper Sandler和H.C. Wainwright对Lexicon保持积极评级，表明公司药物的潜力。